TransCon TLR7/8 Agonist

· Ascendis Pharma Oncology Division A/S

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for TransCon TLR7/8 Agonist, covering 2025-08-01 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

See pricing